Comparative Pharmacology
Head-to-head clinical analysis: ASHLYNA versus NIKITA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASHLYNA versus NIKITA.
ASHLYNA vs NIKITA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ASHLYNA is a combination of ethinyl estradiol and drospirenone. The contraceptive effect is based on inhibition of ovulation and alterations in cervical mucus and endometrial receptivity. Drospirenone has antimineralocorticoid and antiandrogenic activity.
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the serotonin transporter (SERT).
One tablet (0.02 mg ethinyl estradiol / 3 mg drospirenone) orally once daily for 21 days, followed by 7 placebo tablets.
NIKITA is not a recognized pharmaceutical agent; no standard dosing information is available.
None Documented
None Documented
Terminal half-life: 12–15 hours; clinical context: supports once-daily dosing
Terminal elimination half-life is 12 hours (range 10-14 hours); permits twice-daily dosing in most patients with normal renal function.
Renal: ~60% unchanged; fecal: ~30% (metabolites); biliary: ~10%
Primarily renal (approx. 60% unchanged), with biliary/fecal excretion accounting for 30% and minor metabolic clearance.
Category C
Category C
Contraceptive
Contraceptive